Table 1 Baseline characteristics of participants
Characteristic | Treatments | P-valuea, b | ||
|---|---|---|---|---|
Portfolio intensive (n = 101) | Portfolio routine (n = 122) | Control (n = 122) |  | |
Age, mean (SD) y | 54.6 (9.8) | 57.1 (8.3) | 56.9 (9.3) | 0.082 |
Sex | Â | Â | Â | Â |
 Male | 50 (49.5%) | 37 (30.3%) | 47 (38.5%) | 0.014 |
 Female | 51 (50.5%) | 85 (69.7%) | 75 (61.5%) | |
Body weight, mean (SD), kg | 75.5 (13.5) | 73.7 (13.3) | 76.9 (13.8) | 0.189 |
Body mass index, mean (SD), kg/m2 | 26.6 (4.0) | 26.9 (3.8) | 27.4 (3.9) | 0.244 |
Blood pressure, mean (SD), mm Hg | Â | Â | Â | Â |
 Systolic | 120.9 (12.6) | 119.5 (13.5) | 119.9 (11.9) | 0.683 |
 Diastolic | 73.1 (9.0) | 73.8 (8.3) | 73.0 (8.0) | 0.731 |
Lipids, mean (SD), mmol/Lc | Â | Â | Â | Â |
 Total | 6.53 (1.00) | 6.63 (1.06) | 6.45 (0.87) | 0.830 |
 LDL-C | 4.42 (0.89) | 4.50 (0.88) | 4.35 (0.72) | 0.380 |
 HDL-C | 1.42 (0.32) | 1.40 (0.40) | 1.39 (0.36) | 0.836 |
 Triglycerides | 1.53 (0.73) | 1.61 (0.83) | 1.65 (0.98) | 0.574 |
Medication use | Â | Â | Â | Â |
 Lipid lowering medication | 13 (12.9%) | 20 (16.4%) | 18 (14.8%) | 0.754 |
 Antihypertensive medication | 18 (17.8%) | 17 (13.9%) | 28 (23.0%) | 0.193 |
 Hormone-replacement medication | 2 (2%) | 7 (5.7%) | 2 (1.6%) | 0.195 |
 Thyroxine | 9 (8.9%) | 11 (9%) | 15 (12.3%) | 0.627 |